These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27771485)

  • 1. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into co-amorphous systems in therapeutic drug delivery.
    Singh R; Joshi V; Mehetre N; Sangamwar AT
    Ther Deliv; 2021 Mar; 12(3):245-265. PubMed ID: 33745286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermal Stability of Amorphous Solid Dispersions.
    Jelić D
    Molecules; 2021 Jan; 26(1):. PubMed ID: 33466393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical and Computational Methods for the Determination of Drug-Polymer Solubility and Miscibility.
    Thakore SD; Akhtar J; Jain R; Paudel A; Bansal AK
    Mol Pharm; 2021 Aug; 18(8):2835-2866. PubMed ID: 34041914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Application of Modeling and Prediction to the Formation and Stability of Amorphous Solid Dispersions.
    DeBoyace K; Wildfong PLD
    J Pharm Sci; 2018 Jan; 107(1):57-74. PubMed ID: 28389266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
    Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
    Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.
    Edueng K; Mahlin D; Bergström CAS
    Pharm Res; 2017 Sep; 34(9):1754-1772. PubMed ID: 28523384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Assessment of Miniaturized Screening Approaches for Selection of Polymers for Amorphous Drug Stabilization.
    Banda A; Manchanda A; Zhang W; Alba GM; Nagapudi K
    J Pharm Sci; 2018 Mar; 107(3):897-908. PubMed ID: 29155235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.
    Ricarte RG; Van Zee NJ; Li Z; Johnson LM; Lodge TP; Hillmyer MA
    Mol Pharm; 2019 Oct; 16(10):4089-4103. PubMed ID: 31487183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Solubility/Miscibility in Amorphous Dispersions: It Is Time to Move Beyond Regular Solution Theories.
    Anderson BD
    J Pharm Sci; 2018 Jan; 107(1):24-33. PubMed ID: 29031973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L; Tale S; Reineke TM
    Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
    Newman A; Reutzel-Edens SM; Zografi G
    J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miscibility/stability considerations in binary solid dispersion systems composed of functional excipients towards the design of multi-component amorphous systems.
    Yoo SU; Krill SL; Wang Z; Telang C
    J Pharm Sci; 2009 Dec; 98(12):4711-23. PubMed ID: 19462469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Physical Stability of Amorphous Drug Formulations via Dry Polymer Coating.
    Capece M; Davé R
    J Pharm Sci; 2015 Jun; 104(6):2076-2084. PubMed ID: 25902736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.